• Product NameBarasertib (AZD1152-HQPA)
• Brief DescriptionInhibitors
• Purification98.87%
• Biological ActivityBarasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
• Target NameAurora Kinase inhibitor
• CAS No. 722544-51-6
• Calculated MW 507.56
• Formulation C26H30FN7O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CCN(CCO)CCCOC1=CC2=C(C=C1)C(NC1=NNC(CC(=O)NC3=CC(F)=CC=C3)=C1)=NC=N2
  Pathways:Cell Cycle/Checkpoint; Chromatin/Epigenetic
  Receptor:Aurora A; Aurora B
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 3 mg/mL (5.91 mM); DMSO: 102 mg/mL (200.96 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Yang J, et al. Blood, 2007, 110(6), 2034-2040.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting